LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 41

Search options

  1. Book: Clinical approach to antiphospholipid antibodies

    Levine, Steven R. / Brey, Robin L.

    2000  

    Author's details Steven R. Levine ; Robin L. Brey
    Keywords Anti-Phospholipid-Antikörper
    Subject APL-AK
    Language English
    Size XVIII, 147 S. : Ill., graph. Darst.
    Publisher Butterworth-Heinemann
    Publishing place Boston u.a.
    Publishing country United States
    Document type Book
    HBZ-ID HT012019974
    ISBN 0-7506-7177-7 ; 978-0-7506-7177-4
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  2. Article ; Online: Academic Neurology Departments: Structure, Diversity, and Financial Pressures in 2019 vs 2002.

    Brey, Robin L / Ostendorf, Tasha / Rizzo, Matthew / Sacco, Ralph L

    Neurology

    2021  Volume 96, Issue 10, Page(s) 483–490

    MeSH term(s) Faculty ; Faculty, Medical ; Neurology/economics ; Neurology/education ; Schools, Medical/economics ; Schools, Medical/organization & administration ; Surveys and Questionnaires ; United States
    Language English
    Publishing date 2021-01-27
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 207147-2
    ISSN 1526-632X ; 0028-3878
    ISSN (online) 1526-632X
    ISSN 0028-3878
    DOI 10.1212/WNL.0000000000011538
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Neuropsychiatric lupus: clinical and imaging aspects.

    Brey, Robin L

    Bulletin of the NYU hospital for joint diseases

    2007  Volume 65, Issue 3, Page(s) 194–199

    Abstract: Neuropsychiatric lupus (NPSLE) manifestations are common in adults and children and are associated with an increase in both morbidity and mortality. Cognitive dysfunction, when standardly assessed using sensitive neurocognitive instruments, is the most ... ...

    Abstract Neuropsychiatric lupus (NPSLE) manifestations are common in adults and children and are associated with an increase in both morbidity and mortality. Cognitive dysfunction, when standardly assessed using sensitive neurocognitive instruments, is the most common NPSLE manifestation. The pathogenic etiologies of NPSLE manifestations are likely to be multifactorial and may involve autoantibody production, microangiopathy, intrathecal production of proinflammatory cytokines and athersclerosis. It is becoming more clear that the integrity of the blood-brain-barrier is very important in SLE-related neuropathology. Brain imaging is an important tool that allows us to evaluate the living brain. Thus far, anatomic brain imaging has revealed abnormalities such as subcortical white matter lesions and cerebral atrophy, but these findings are non-specific. Methods that evaluate metabolic processes and other functional imaging techniques have more promise as surrogates for central nervous system damage. This article reviews the current literature on clinical and imaging aspects of NPSLE.
    MeSH term(s) Animals ; Brain/pathology ; Cognition Disorders/etiology ; Cognition Disorders/pathology ; Humans ; Lupus Vasculitis, Central Nervous System/complications ; Lupus Vasculitis, Central Nervous System/pathology ; Magnetic Resonance Imaging ; Magnetic Resonance Spectroscopy ; Sensitivity and Specificity ; Tomography, Emission-Computed
    Language English
    Publishing date 2007
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 390411-8
    ISSN 2328-5273 ; 1936-9727 ; 1936-9719 ; 0018-5647 ; 0883-9344 ; 2328-4633
    ISSN (online) 2328-5273 ; 1936-9727
    ISSN 1936-9719 ; 0018-5647 ; 0883-9344 ; 2328-4633
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Antiphospholipid antibodies in young adults with stroke.

    Brey, Robin L

    Journal of thrombosis and thrombolysis

    2005  Volume 20, Issue 2, Page(s) 105–112

    Abstract: Background: Antiphospholipid antibodies have been associated with a clinical syndrome consisting thrombosis and recurrent, unexplained fetal loss.: Methods: The literature pertaining to stroke associated with antiphospholipid antibodies, with ... ...

    Abstract Background: Antiphospholipid antibodies have been associated with a clinical syndrome consisting thrombosis and recurrent, unexplained fetal loss.
    Methods: The literature pertaining to stroke associated with antiphospholipid antibodies, with emphasis on stroke in young adults, was reviewed.
    Results: Antiphospholipid antibodies are an independent risk factor for stroke in young adults in five of six studies. Multiple antiphospholipid specificities or the Lupus Anticoagulant were tested in addition to anticardiolipin antibody in these studies. In the single study that found no increased risk for stroke, only anticardiolipin antibody was tested. Only one of these studies evaluated for risk of recurrent stroke in young adults with antiphospholipid antibodies and found it to be increased. No treatment trials have been conducted in young adults with antiphospholipid antibodies and stroke. In the single treatment trial comparing aspirin and low-INR producing doses of warfarin to prevent recurrent stroke, both were found to be equally effective.
    Conclusions: Antiphospholipid antibodies, particularly Lupus Anticoagulant, is an independent risk factor for first and possibly recurrent ischemic stroke in young adults. The best therapeutic strategy for preventing antiphospholipid antibody-associated recurrent stroke is not clear.
    MeSH term(s) Adolescent ; Adult ; Age Factors ; Antibodies, Anticardiolipin/blood ; Antibodies, Antiphospholipid/blood ; Anticoagulants/therapeutic use ; Antiphospholipid Syndrome/genetics ; Antiphospholipid Syndrome/immunology ; Antiphospholipid Syndrome/therapy ; Aspirin/therapeutic use ; Humans ; Ischemic Attack, Transient/blood ; Ischemic Attack, Transient/immunology ; Ischemic Attack, Transient/prevention & control ; Lupus Coagulation Inhibitor/blood ; Platelet Aggregation Inhibitors/therapeutic use ; Randomized Controlled Trials as Topic ; Risk Factors ; Secondary Prevention ; Stroke/blood ; Stroke/immunology ; Stroke/prevention & control ; Thrombosis/immunology ; Thrombosis/prevention & control ; Warfarin/therapeutic use
    Chemical Substances Antibodies, Anticardiolipin ; Antibodies, Antiphospholipid ; Anticoagulants ; Lupus Coagulation Inhibitor ; Platelet Aggregation Inhibitors ; Warfarin (5Q7ZVV76EI) ; Aspirin (R16CO5Y76E)
    Language English
    Publishing date 2005-10
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 1230645-9
    ISSN 0929-5305
    ISSN 0929-5305
    DOI 10.1007/s11239-005-3204-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Patient page. Exercise is safe and beneficial for people with facioscapulohumeral muscular dystrophy.

    Brey, Robin L

    Neurology

    2005  Volume 64, Issue 6, Page(s) E22

    MeSH term(s) Disease Progression ; Exercise/physiology ; Exercise Therapy/standards ; Female ; Humans ; Male ; Muscle, Skeletal/pathology ; Muscle, Skeletal/physiology ; Muscle, Skeletal/physiopathology ; Muscular Dystrophy, Facioscapulohumeral/genetics ; Muscular Dystrophy, Facioscapulohumeral/physiopathology ; Muscular Dystrophy, Facioscapulohumeral/rehabilitation ; Physical Fitness/physiology
    Language English
    Publishing date 2005-01-25
    Publishing country United States
    Document type Journal Article ; Patient Education Handout
    ZDB-ID 207147-2
    ISSN 1526-632X ; 0028-3878
    ISSN (online) 1526-632X
    ISSN 0028-3878
    DOI 10.1212/wnl.64.6.e22
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Both migraine and motion sickness may be due to low brain levels of serotonin.

    Brey, Robin L

    Neurology

    2005  Volume 65, Issue 4, Page(s) E9–10

    Abstract: Scientists believe that low levels of a brain chemical called serotonin may make people susceptible to developing migraine headaches. Many people with migraine also have a problem with motion sickness, but it is not clear why this might be. We know that ... ...

    Abstract Scientists believe that low levels of a brain chemical called serotonin may make people susceptible to developing migraine headaches. Many people with migraine also have a problem with motion sickness, but it is not clear why this might be. We know that many drugs to treat motion sickness increase brain levels of serotonin, an important brain chemical. It is possible that low brain levels of serotonin may also be responsible for motion sickness. In this issue of Neurology, Drummond reports on a study that evaluated whether low brain levels of serotonin trigger motion sickness in people with and without migraine. More information about migraine can be found on the next page.
    MeSH term(s) Brain/drug effects ; Brain/metabolism ; Brain/physiopathology ; Brain Chemistry/drug effects ; Brain Chemistry/physiology ; Clinical Trials as Topic/statistics & numerical data ; Humans ; Migraine Disorders/etiology ; Migraine Disorders/metabolism ; Migraine Disorders/physiopathology ; Motion Sickness/etiology ; Motion Sickness/metabolism ; Motion Sickness/physiopathology ; Serotonin/deficiency ; Treatment Outcome ; Tryptophan/therapeutic use
    Chemical Substances Serotonin (333DO1RDJY) ; Tryptophan (8DUH1N11BX)
    Language English
    Publishing date 2005-08-23
    Publishing country United States
    Document type Journal Article ; Patient Education Handout
    ZDB-ID 207147-2
    ISSN 1526-632X ; 0028-3878
    ISSN (online) 1526-632X
    ISSN 0028-3878
    DOI 10.1212/01.wnl.0000176949.34080.64
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Management of the neurological manifestations of APS--what do the trials tell us?

    Brey, Robin L

    Thrombosis research

    2004  Volume 114, Issue 5-6, Page(s) 489–499

    Abstract: Purpose: To systematically review evidence from clinical trials about the management of neurological manifestations of Antiphospholipid Syndrome (APS).: Methods: Articles reporting case-control, cohort and prospective studies and treatment trials of ... ...

    Abstract Purpose: To systematically review evidence from clinical trials about the management of neurological manifestations of Antiphospholipid Syndrome (APS).
    Methods: Articles reporting case-control, cohort and prospective studies and treatment trials of primary or secondary stroke prevention in patients with aPL were identified in an OVID literature search from 1966 to 2004, using the keywords: APS, aPL and cerebrovascular disease. Articles were evaluated according to the standard system for assessing medical evidence to answer the following questions: (1) What is the role of aPL and recurrent stroke risk in both primary and secondary APS populations? (2) What is the evidence to support specific treatment strategies for secondary prevention of aPL-associated stroke? (3) What is the evidence to support specific treatment strategies for primary prevention of aPL-associated stroke?
    Conclusions: (1) aPL are a risk factor for incident stroke (Grade A, established as useful for the given condition in the specified population). (2) The evidence to support the role of aPL in recurrent stroke is conflicting and, therefore, inconclusive. (3) Warfarin at moderate-intensity doses is equally effective in preventing a recurrent thrombotic event as warfarin at high-intensity doses in patients with APS (Grade A evidence, established as useful for the given condition in the specified population). (4) Warfarin, at moderate-intensity doses is as effective as aspirin (at a dose of 325 mg/day) in preventing recurrent thrombotic events in patients who are aPL-positive at the time of an initial stroke (Grade B evidence, probably useful for the given condition in the given population). (5) Currently there are no data to support the use of any prophylactic therapy in patients with aPL and no clinical manifestations for the purposes of preventing an incident stroke.
    MeSH term(s) Adult ; Antibodies, Antiphospholipid/chemistry ; Antiphospholipid Syndrome/therapy ; Case-Control Studies ; Cerebrovascular Disorders/immunology ; Clinical Trials as Topic ; Cohort Studies ; Female ; Humans ; Male ; Middle Aged ; Prospective Studies ; Recurrence ; Risk Factors ; Stroke/etiology ; Stroke/prevention & control ; Thrombosis ; Warfarin/therapeutic use
    Chemical Substances Antibodies, Antiphospholipid ; Warfarin (5Q7ZVV76EI)
    Language English
    Publishing date 2004
    Publishing country United States
    Document type Journal Article ; Research Support, U.S. Gov't, P.H.S. ; Review
    ZDB-ID 121852-9
    ISSN 1879-2472 ; 0049-3848
    ISSN (online) 1879-2472
    ISSN 0049-3848
    DOI 10.1016/j.thromres.2004.06.018
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Patient Page. Clinical research needs YOU to help develop new cures!

    Brey, Robin L

    Neurology

    2004  Volume 63, Issue 1, Page(s) E1

    MeSH term(s) Clinical Trials as Topic/psychology ; Clinical Trials as Topic/trends ; Humans ; Nervous System Diseases/therapy ; Patients/psychology ; Volunteers
    Language English
    Publishing date 2004-04-30
    Publishing country United States
    Document type Journal Article ; Patient Education Handout
    ZDB-ID 207147-2
    ISSN 1526-632X ; 0028-3878
    ISSN (online) 1526-632X
    ISSN 0028-3878
    DOI 10.1212/01.wnl.0000133904.76001.78
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Patient page. Long-term obesity is linked to loss of brain tissue.

    Brey, Robin L

    Neurology

    2004  Volume 63, Issue 10, Page(s) E19–20

    MeSH term(s) Aged ; Aged, 80 and over ; Aging/psychology ; Atrophy ; Brain/diagnostic imaging ; Brain/pathology ; Chronic Disease ; Comorbidity ; Dementia/classification ; Dementia/diagnosis ; Dementia/epidemiology ; Diabetes Mellitus/epidemiology ; Early Diagnosis ; Female ; Follow-Up Studies ; Humans ; Hypertension/epidemiology ; Obesity/epidemiology ; Sweden/epidemiology ; Tomography, X-Ray Computed
    Language English
    Publishing date 2004-11-04
    Publishing country United States
    Document type Journal Article ; Patient Education Handout
    ZDB-ID 207147-2
    ISSN 1526-632X ; 0028-3878
    ISSN (online) 1526-632X
    ISSN 0028-3878
    DOI 10.1212/01.wnl.0000148952.71557.bf
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Patient page. Cigarette smoking and multiple sclerosis (MS): yet another reason to quit.

    Brey, Robin L

    Neurology

    2003  Volume 61, Issue 8, Page(s) E11–2

    MeSH term(s) Adult ; Comorbidity/trends ; Female ; Humans ; Male ; Middle Aged ; Multiple Sclerosis/diagnosis ; Multiple Sclerosis/epidemiology ; Multiple Sclerosis/therapy ; Norway/epidemiology ; Risk ; Risk Factors ; Smoking/epidemiology
    Language English
    Publishing date 2003-10-28
    Publishing country United States
    Document type Journal Article ; Patient Education Handout
    ZDB-ID 207147-2
    ISSN 1526-632X ; 0028-3878
    ISSN (online) 1526-632X
    ISSN 0028-3878
    DOI 10.1212/wnl.61.8.e11
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top